Find Aprocitentan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1103522-45-7, Act-132577, Aprocitentan [usan], Macitentan metabolite m6, Mzi81hv01p, 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
Molecular Formula
C16H14Br2N6O4S
Molecular Weight
546.2  g/mol
InChI Key
DKULOVKANLVDEA-UHFFFAOYSA-N
FDA UNII
MZI81HV01P

Aprocitentan
Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).
1 2D Structure

Aprocitentan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine
2.1.2 InChI
InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24)
2.1.3 InChI Key
DKULOVKANLVDEA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br
2.2 Other Identifiers
2.2.1 UNII
MZI81HV01P
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Act-132577

2. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfuric Diamide

3. Sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-

2.3.2 Depositor-Supplied Synonyms

1. 1103522-45-7

2. Act-132577

3. Aprocitentan [usan]

4. Macitentan Metabolite M6

5. Mzi81hv01p

6. 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine

7. Chembl2165326

8. Chebi:76609

9. N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric Diamide

10. N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide

11. Sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-

12. Despropyl Macitentan

13. N-despropyl-macitentan

14. Unii-mzi81hv01p

15. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfamide

16. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfuric Diamide

17. Act 132577

18. Aprocitentan (usan/inn)

19. Aprocitentan [inn]

20. Schembl3646065

21. Aprocitentan (act-132577)

22. Gtpl10070

23. Amy39078

24. Bcp28125

25. Ex-a4419

26. Bdbm50395672

27. Who 10552

28. Zinc95553608

29. Db15059

30. Ncgc00378592-01

31. Ac-36529

32. As-82256

33. Hy-15895

34. Db-130379

35. D11441

36. D87138

37. A922313

38. Q27146161

39. Act-132577; Act 132577; Act132577

40. 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine.

41. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-sulfamide

42. N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfuric Diamide

43. N-(5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamide

2.4 Create Date
2008-12-15
3 Chemical and Physical Properties
Molecular Weight 546.2 g/mol
Molecular Formula C16H14Br2N6O4S
XLogP32.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count8
Exact Mass545.91435 g/mol
Monoisotopic Mass543.91640 g/mol
Topological Polar Surface Area151 Ų
Heavy Atom Count29
Formal Charge0
Complexity597
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of hypertension


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

02

Zhejiang Hengkang Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Zhejiang Hengkang Pharmaceutical

03

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

04

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner

05

Enaltec Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEnaltec Labs –Delivering complex APIs with precision, innovation, and global compliance.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

06

Daishang Pharmchem Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AOCS Annual Meeting
Not Confirmed
arrow

Daishang Pharmchem Group

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AOCS Annual Meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Nifty Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AOCS Annual Meeting
Not Confirmed
arrow

Nifty Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AOCS Annual Meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AOCS Annual Meeting
Not Confirmed
arrow

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AOCS Annual Meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

09

Apino Pharma

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AOCS Annual Meeting
Not Confirmed
arrow

Apino Pharma

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AOCS Annual Meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

AOCS Annual Meeting
Not Confirmed
arrow

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
AOCS Annual Meeting
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

HOVIONE LLC

Portugal
AOCS Annual Meeting
Not Confirmed
arrow

HOVIONE LLC

Portugal
arrow
AOCS Annual Meeting
Not Confirmed

APROCITENTAN

NDC Package Code : 42052-1703

Start Marketing Date : 2024-03-19

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Aprocitentan, a miscellaneous product targeting ET-A and ET-B, shows promise in treating resistant hypertension.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jeraygo

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 05, 2026

blank

01

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Aprocitentan, a miscellaneous product targeting ET-A and ET-B, shows promise in treating resistant hypertension.

Product Name : Jeraygo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 05, 2026

blank

Details:

Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 09, 2025

blank

02

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension.

Product Name : Tryvio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 09, 2025

blank

Details:

Ethinyl estradiol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Ethinyl Estradiol,Levonorgestrel,Aprocitentan

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 29, 2025

blank

03

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Ethinyl estradiol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 29, 2025

blank

Details:

Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in adult patients, in combination with other antihypertensive drugs.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 15, 2024

blank

04

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in adult patients, in combination with other antihypertensive drugs.

Product Name : Tryvio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 15, 2024

blank

Details:

Jeraygo (aprocitentan), the first endothelin receptor antagonist, treats hypertension in adults by combining it with other antihypertensives to reduce blood pressure.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jeraygo

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 26, 2024

blank

05

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Jeraygo (aprocitentan), the first endothelin receptor antagonist, treats hypertension in adults by combining it with other antihypertensives to reduce blood pressure.

Product Name : Jeraygo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 26, 2024

blank

Details:

Tryvio (aprocitentan), an endothelin receptor antagonist, is indicated for treating hypertension when combined with other antihypertensives to lower blood pressure in adults.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 20, 2024

blank

06

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Tryvio (aprocitentan), an endothelin receptor antagonist, is indicated for treating hypertension when combined with other antihypertensives to lower blood pressure in adults.

Product Name : Tryvio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 20, 2024

blank

Details:

Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janssen.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Idorsia Pharmaceuticals

Deal Size: $343.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement September 05, 2023

blank

07

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janss...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

September 05, 2023

blank

Details:

ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: JANSSEN BIOTECH

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 31, 2023

blank

08

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.

Product Name : Tryvio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 31, 2023

blank

Details:

ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tryvio

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 20, 2022

blank

09

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.

Product Name : Tryvio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 20, 2022

blank

Details:

Aprocitentan (ACT-132577), a novel, dual ERA, which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is intended to address the pathophysiology of difficult-to-control HTN.


Lead Product(s): Aprocitentan,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Idorsia Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 07, 2022

blank

10

Arvo
Not Confirmed
Arvo
Not Confirmed

Details : Aprocitentan (ACT-132577), a novel, dual ERA, which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is intended to address the pathophysiology of di...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 07, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

APROCITENTAN

Brand Name : TRYVIO

Dosage Form : TABLET;ORAL

Dosage Strength : 12.5MG

Packaging :

Approval Date : 2024-03-19

Application Number : 217686

Regulatory Info : RX

Registration Country : USA

blank

02

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Approaching \"Medical Valley\"

Dosage Form : Hard Capsules

Dosage Strength : 125mg; 80mg

Packaging :

Approval Date : 03-05-2019

Application Number : 28106256517

Regulatory Info : Prescription

Registration Country : Denmark

blank

03

Merck & Co

U.S.A
Arvo
Not Confirmed
arrow

Merck & Co

U.S.A
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Emend

Dosage Form : Hard Capsules

Dosage Strength : 125mg

Packaging :

Approval Date : 11-11-2003

Application Number : 28103454302

Regulatory Info : Prescription

Registration Country : Denmark

blank

04

Merck & Co

U.S.A
Arvo
Not Confirmed
arrow

Merck & Co

U.S.A
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Emend

Dosage Form : Oral Suspension Powder

Dosage Strength : 125mg

Packaging :

Approval Date : 16-12-2015

Application Number : 28105550214

Regulatory Info : Prescription

Registration Country : Denmark

blank

05

Merck & Co

U.S.A
Arvo
Not Confirmed
arrow

Merck & Co

U.S.A
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Emend

Dosage Form : Hard Capsules

Dosage Strength : 125mg; 80mg

Packaging :

Approval Date : 11-11-2003

Application Number : 28103605502

Regulatory Info : Prescription

Registration Country : Denmark

blank

06

Sandoz B2B

Switzerland
Arvo
Not Confirmed
arrow

Sandoz B2B

Switzerland
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : The Flavoring \"Sandoz\"

Dosage Form : Hard Capsules

Dosage Strength : 125mg; 80mg

Packaging :

Approval Date : 21-06-2018

Application Number : 28105898416

Regulatory Info : Prescription

Registration Country : Denmark

blank

07

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Abbreviation \"Stada\"

Dosage Form : Hard Capsules

Dosage Strength : 125mg

Packaging :

Approval Date : 15-02-2019

Application Number : 28105978917

Regulatory Info : Prescription

Registration Country : Denmark

blank

08

Arvo
Not Confirmed
arrow
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Abbreviation \"Stada\"

Dosage Form : Hard Capsules

Dosage Strength : 125mg; 80mg

Packaging :

Approval Date : 15-02-2019

Application Number : 28106228217

Regulatory Info : Prescription

Registration Country : Denmark

blank

09

Country
Arvo
Not Confirmed
arrow

Country
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Jeraygo

Dosage Form : Film-Coated Tablet

Dosage Strength : 125mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

10

Country
Arvo
Not Confirmed
arrow

Country
arrow
Arvo
Not Confirmed

Aprocitentan

Brand Name : Jeraygo

Dosage Form : Film-Coated Tablet

Dosage Strength : 25mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

IDORSIA

Switzerland
Arvo
Not Confirmed
arrow

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

Brand Name : TRYVIO

Dosage Form : TABLET;ORAL

Dosage Strength : 12.5MG

Approval Date : 2024-03-19

Application Number : 217686

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 8324232

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217686

Patent Use Code : U-3878

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-09-21

blank

02

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 12297189

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 217686

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-02-26

blank

03

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 10919881

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217686

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-02-26

blank

04

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 11787782

Drug Substance Claim :

Drug Product Claim :

Application Number : 217686

Patent Use Code : U-3877

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-03-02

blank

05

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 11680058

Drug Substance Claim :

Drug Product Claim :

Application Number : 217686

Patent Use Code : U-3878

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-07-26

blank

06

arrow
Arvo
Not Confirmed

IDORSIA

Switzerland
arrow
Arvo
Not Confirmed

APROCITENTAN

US Patent Number : 11174247

Drug Substance Claim :

Drug Product Claim :

Application Number : 217686

Patent Use Code : U-3879

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-11-06

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1103522-45-7 / Aprocitentan API manufacturers, exporters & distributors?

Aprocitentan manufacturers, exporters & distributors 1

32

PharmaCompass offers a list of Aprocitentan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aprocitentan manufacturer or Aprocitentan supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aprocitentan manufacturer or Aprocitentan supplier.

API | Excipient name

Aprocitentan

Synonyms

1103522-45-7, Act-132577, Aprocitentan [usan], Macitentan metabolite m6, Mzi81hv01p, 5-(4-bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine

Cas Number

1103522-45-7

Unique Ingredient Identifier (UNII)

MZI81HV01P

About Aprocitentan

Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).

Aprocitentan Manufacturers

A Aprocitentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aprocitentan, including repackagers and relabelers. The FDA regulates Aprocitentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aprocitentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Aprocitentan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Aprocitentan Suppliers

A Aprocitentan supplier is an individual or a company that provides Aprocitentan active pharmaceutical ingredient (API) or Aprocitentan finished formulations upon request. The Aprocitentan suppliers may include Aprocitentan API manufacturers, exporters, distributors and traders.

click here to find a list of Aprocitentan suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Aprocitentan NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aprocitentan as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Aprocitentan API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Aprocitentan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Aprocitentan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aprocitentan NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Aprocitentan suppliers with NDC on PharmaCompass.

Aprocitentan GMP

Aprocitentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Aprocitentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Aprocitentan GMP manufacturer or Aprocitentan GMP API supplier for your needs.

Aprocitentan CoA

A Aprocitentan CoA (Certificate of Analysis) is a formal document that attests to Aprocitentan's compliance with Aprocitentan specifications and serves as a tool for batch-level quality control.

Aprocitentan CoA mostly includes findings from lab analyses of a specific batch. For each Aprocitentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Aprocitentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Aprocitentan EP), Aprocitentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aprocitentan USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty